B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression

Clinical Cancer Research

Volumn 10, Issue 15, 2004, Pages 5094-5100

  Konishi, Jun ^a   Yamazaki, Koichi ^a   Azuma, Miyuki ^b   Kinoshita, Ichiro ^c   Dosaka Akita, Hirotoshi ^c   Nishimura, Masaharu ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; B7 H1 ANTIGEN; CD28 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; LIGAND; RECEPTOR PD1; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CLINICAL FEATURE; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; JAPAN; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL CULTURE;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, CD45; ANTIGENS, CD80; ANTIGENS, SURFACE; ANTINEOPLASTIC AGENTS; APOPTOSIS REGULATORY PROTEINS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIGANDS; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PEPTIDES; T-LYMPHOCYTES;

EID: 4243096258     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0428     Document Type: Article

References (34)

1. Ginsberg RJ, Vokes EE, Raben A. Non-small cell lung cancer. In: De Vita VT, Hellmann S, Rosenberg SA, editors. Cancer: principles and practice of oncology, 6th ed. Philadelphia: Lippincott-Raven Publishers; 2001. p. 858-910.
2. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996;17:138-46.
3. Sperling AI, Bluestone JA. The complexities of T-cell co-stimulation: CD28 and beyond. Immunol Rev 1996;153:155-82.
4. Ravetch JV, Lanier LL. Immune inhibitory receptors. Science (Wash DC) 2000;290:84-9.
5. Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin 10 secretion. Nat Med 1999;5:1365-9.
6. Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001;2:261-8.
7. Carreno BM, Collins M. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu Rev Immunol 2002;20:29-53.
8. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000;192: 1027-34.
9. + T cells and is overcome by IL-2. Eur J Immunol 2002;32:3376-85.
10. Nishimura H, Honjo T. PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol 2001;22:265-8.
11. Nishimura H, Nose M, Hirai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999;11: 141-51.
12. Brown JA, Dorfman DM, Ma FR, et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 2003;170:1257-66.
13. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8:793-800.
14. Liang SC, Latchman YE, Buhlmann JE, et al. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol 2003;33:2706-16.
15. Agata Y, Kawasaki A, Nishimura H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 1996;8:765-72.
16. Wintterle S, Screiner B, Mitsdoerffer M, et al. Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res 2003;63:7462-7.
17. Strome SE, Dong H, Tamura H, et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res 2003;63:6501-5.
18. Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 2002;99:12293-7.
19. World Health Organization. Histological typing of lung tumors, ed. 2. Am J Clin Pathol 1982;77:123-36.
20. American Joint Committee on Cancer. Lung. In: Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ, editors. Manual for staging of cancer. Philadelphia: Lippincott; 1992. p. 115-22.
21. Youngnak P, Kozono Y, Kozono H, et al. Differential binding properties of B7-H1 and B7-DC to programmed death-1. Biochem Biophys Res Commun 2003;307:672-7.
22. Bennett MW, O'Connell J, O'Sullivan GC, et al. The Fas counter-attack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol 1998;160:5669-75.
23. Chen XL, Cao XD, Kang AJ, et al. In situ expression and significance of B7 costimulatory molecules within tissues of human gastric carcinoma. World J Gastroenterol 2003;6:1370-3.
24. Yamazaki K, Spruill G, Rhoderick J, et al. Small cell lung carcinomas express shared and private tumor antigens presented by HLA-A1 or HLA-A2. Cancer Res 1999;59:4642-50.
25. Wu TC, Huang AYC, Jaffee EM, Levitsky HI, Pardoll DM. A reassessment of the role of B7-1 expression in tumor rejection. J Exp Med 1995;182:1415-21.
26. Redondo M, Concha A, Oldiviela R, et al. Expression of HLA class I and II antigens in bronchogenic carcinomas: its relationship to cellular DNA content and clinical-pathological parameters. Cancer Res 1991; 51:4948-54.
27. Samuels V, Barrett JM, Bockman S, Pantazis CG, Allen MB Jr. Immunocytochemical study of transforming growth factor expression in benign and malignant glioma. Am J Pathol 1989;134:894-902.
28. Huettner C, Paulus W, Roggendorf W. Messenger RNA expression of the immunosuppressive cytokine IL-10 in human gliomas. Am J Pathol 1995;146:317-22.
29. Smyth MJ, Godfey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2001;2:293-9.
30. Oizumi S, Yamazaki K, Nakashima M, et al. RCAS1 expression: a potential prognostic marker for adenocarcinoma of the lung. Oncology (Basel) 2002;62:333-9.
31. Hahne M, Rimoldi D, Schroter M, et al. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science (Wash DC) 1996;274:1363-6.
32. Curiel TJ, Wei S, Dong H, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity Nat Med 2003;9: 562-7.
33. Tseng SY, Otsuji M, Gorski K, et al. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med 2001;193:839-45.
34. Liu X, Gao JX, Wen J, et al. B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism. J Exp Med 2003;197:1721-30.